The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence - Data from the Utah Cancer Registry

Cancer

Volumn 77, Issue 7, 1996, Pages 1342-1348

  Stephenson, Robert A ^a,f   Smart, Charles R ^b   Mineau, Geraldine P ^c   James, Brent C ^d   Janerich, Dwight T ^e   Dibble, Rosemary L ^b  

^a Utah Cancer Registry ^*  (United States)

^b UTAH CANCER REGISTRY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Institute for Health Care Delivery Research   (United States)

^e FOUNDATION FOR BLOOD RESEARCH   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

incidence; mortality; prostate carcinoma; prostate specific antigen; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER INCIDENCE; DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; UNITED STATES;

AGE FACTORS; AGED; EPIDEMIOLOGY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; SEER PROGRAM; UTAH;

EID: 0029876829     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1342::AID-CNCR18>3.0.CO;2-1     Document Type: Article

References (50)

1. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK. SEER cancer statistics review: tables and graphs, 1973-1991. Bethesda (MD): National Institutes of Health, National Cancer Institute; 1994 Report No.: NIH-94-2789.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273:548-52.
3. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993; 269:61-4.
4. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995; 273:289-94.
5. Crawford ED, DeAntoni EP. PSA as a screening test for prostate cancer. Urol Clin North Am 1993; 20:637-46.
6. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147:841-5.
7. Catalona WJ, Smith DS, Basler JW. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993; 270:948-54.
8. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-90.
9. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152:1732-6.
10. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Int Med 1993; 119:914-23.
11. Littrup PJ, Lee F, Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin 1992; 42:198-211.
12. Chodak GW. Screening and early detection of prostate cancer. Cancer 1993; 71:981-3.
13. Gerber GS and Chodak GW. Value of prostate cancer screening. Eur Urol 1993;24:161-5.
14. Resnick MI. Controversies on screening for cancer of the prostate. Mr Sinai J Med 1993; 60:412-6.
15. Small EJ. Prostate cancer: who to screen, and what the results mean. Geriatrics 1993; 43:28-30.
16. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA Cancer J Clin 1992; 42:19-43.
17. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43:7-26.
18. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44:7-26.
19. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45:8-30.
20. Woolf SH. Public health perspective: the health policy implications of screening for prostate cancer. J Urol 1994; 152: 1685-8.
21. Feightner JW. The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the periodic health examination. J Urol 1994; 152:1682-4.
22. Benoit RM, Naslaund MJ. An economic rationale for prostate cancer screening. Urology 1994; 44:795-803.
23. Torp-Pederson ST, Littrup PJ, Lee F, Mettlin C. Early prostate cancer: diagnostic costs of screening transrectal US and digital rectal examination. Radiology 1988; 169:351-4.
24. Bilgrami S, Greenberg B. Cost-effectiveness of prostate cancer screening and treatment (letter). Ann Intern Med 1993; 119:1054-5.
25. Fleming C, Wasson JH, Albertson PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269:2650-8.
26. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152:1894-9.
27. Chodak GW, Thisted RA. Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330:242-8.
28. Johannson FE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1993; 267:2191-6.
29. Adolfsson F, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993; 72:310-22.
30. Egawa S, Go M, Kuwao S, Shoji K, Uchida T, Koshiba K. Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan. Urology 1993; 42:520-6.
31. Whitmore WF. Conservative approaches to the management of localized prostatic cancer. Cancer 1993; 71.970-3.
32. Chisholm GD, Rana A. Is the outcome of conservative management for localized prostate cancer acceptable? An overview. Eur Urol 1993;24 (Suppl 2):64-6.
33. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343:251-4
34. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23:211-22.
35. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic rests. J Urol 1994; 152: 1714-20.
36. Cancer in Utah 1966-1990. Publication of the Utah Cancer Registry, 1992. Salt Lake City (Utah): Utah Cancer Registry; 1992 .
37. Baker LH. Breast cancer detection demonstration project: five year summary report. CA Cancer J Clin 1982; 32:196-229.
38. Dodd GD. American Cancer Society guidelines on screening for breast cancer: an overview. Cancer 1992; 69:1886-7.
39. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. N Engl J Med 1992; 327:319-28
40. Miller BA, Feuer EJ, Hankey BF. Recent trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 1993;43:27-41.
41. Duffy SW, Tabar L, Fagerberg, Gad A, Grontoft O, South MC, et al. Breast screening, prognostic factors and survival-results from the Swedish two county study. Br J Cancer 1992; 64:1133-8.
42. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: the health insurance plan project and its sequel-1963-1986. Baltimore: Johns Hopkins University Press, 1988.
43. Stephenson RA, Smart CR, James BC, Mineau G, Janerich DT, Dibble R. The fall in incidence of prostate cancer: on the down side of a PSA detection/screening induced peak in incidence-data from the Utah Cancer Registry. J Urol 1995; 153:416A.
44. Gilliland FD, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates. Am J Epidemiol 1995; 141:275.
45. Stanford JL, Wicklund KG, Blumenstein BA, Brawer MK. The changing epidemiology of prostate cancer in the Seattle-Puget Sound region, 1974-1993. J Urol 1995; 153:504A.
46. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 1995; 4:797-800.
47. Laara E, Day NE, Hakama M. Trends in the mortality from cervical cancer in the Nordic countries: association with organized screening programmes. Lancet 1987; 1(8544):1247-9.
48. Johannesson G, Geirsson G, Day N. The effect of mass screening in Iceland, 1965-1974, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978;21:418-25.
49. Sigurdsson K. Effect of organized screening on the risk of cervical cancer: evaluation of screening activity in Iceland. Int J Cancer 1993; 54:563-70.
50. Benedet JL, Anderson MB, Matisic JP. A comprehensive program for cervical cancer detection and management. J Obstet Gynecol 1992; 166:1254-9.